Correvio Pharma (CORV) Misses Q3 EPS by 6c, Revenues Miss

Correvio Pharma (NASDAQ: CORV) reported Q3 EPS of ($0.23), $0.06 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $6.67 million versus the consensus estimate of $8.82 million.

"On the commercial front, our marketed products portfolio has generated $21.3 million year-to-date in 2019, with $6.7 million of that occurring in the third quarter, and we remain on track for 2019 full year revenues to deliver 20% growth over our 2018 full year revenues," said Mark H.N. Corrigan, MD, Chief Executive Officer of Correvio. "As we look ahead to the remainder of 2019, we are actively preparing for the upcoming meeting of the U.S. Food and Drug Administration (FDA)'s Cardiovascular and Renal Drugs Advisory Committee (CRDAC) to review the data supporting our New Drug Application (NDA) requesting approval for Brinavess which is scheduled for December 10, 2019. We also look forward to presenting an additional analysis from SPECTRUM which looked specifically at patients treated in emergency departments at the upcoming American Heart Association (AHA) 2019 Annual Meeting in November."

For earnings history and earnings-related data on Correvio Pharma (CORV) click here.

You May Also Be Interested In

• Vivos Therapeutics posts 35% revenue gain but widens net loss
• Evogene chairman to address dissident shareholders on results call
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c